| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Red Light Holland Corp. (OTCQB:TRUFF) (CSE:TRIP) (FSE:4YX) has in collaboration with NUBU Pharmaceutical, published a report aimed at educating law makers and a network of medical doctors in Australasia, about the potential benefits of microdosing psilocybin, based on the latest scientific research.
The report will be presented to NUBU's networks of medical doctors in both Australia and New Zealand, providing a summary of the latest scientific research, best practices, and guidelines to help inform doctors who are interested in helping their patients explore microdosing natural psilocybin for potentially therapeutic benefits. The published report also draws on consensual data collection via Red Light Holland's iMicro app and microdosing events in the Netherlands, as well as the knowledge and experience of the company's therapist and microdosing expert, Jeff Hamburg.
Red Light Holland has previously signed a distribution agreement with NUBU Pharmaceuticals to explore the possibility of legal import and distribution of Red Light Holland's psilocybin microdosing capsules to Australasia.
Australia announced on February 3, 2023, a down-listing of psilocybin in its list of controlled substances to allow psychiatrists to prescribe psilocybin to patients suffering from treatment resistant depression. The change in scheduling was announced to take effect on July 1, 2023.
The report can be viewed at this link: A Basic Guide to Microdosing.
Photo: Benzinga edit with photo by geralt on pixabay
Related News
Mia Khalifa Joins Magic Mushrooms Company, Here's What She'll Be Doing
